ASCO 2020：11项中国研究工作入选口头报告，17项Poster报告

所致全球新近冠疫情影响，按计划于5翌年29日~6翌年2日在芝加哥举行的American诊疗学就会（ASCO）年就会本年将首次以终点站上基本举办，这是现有最大规模的终点站上盛就会。从前，开就会的摘录题目公布，共103个sessions，中都国总共11项研究课题崭露头角口头报告，17项崭露头角Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或拉帕替尼加卡培他中洲用作HER2+白血病胰脏症（PHOEBE）：一项III期随机测试。

专场：白血病胰脏症

原作者：中都国医学科学院该医院徐兵河客座教授、马飞客座教授，南京大学附属该医院胡夕春客座教授等

摘录号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴适度胰脏症标准病患后卡培他中洲依靠节奏化学疗法的III期测试（SYSUCC-001）。

专场：胰脏症—大面积/地带/除此以外病患

原作者：清华大学防治中都心王树森客座教授等

摘录号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用白血病脑的表型基本特征来分析脑脊液中都尿素DNA检测的概率: 新近物件对抗老对手

专场：新近物件化解老问题

原作者：李美芹 李德兰等

摘录号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对马利拉非尼作为中都期脂质内胰脏的三终点站病患：一项对外开放标签、随机、多中都心II/III期测试。

专场：肾脏胰脏—胃十二指肠、血栓和实是

原作者：四川大学宝兴该医院毕锋客座教授、解放军八一该医院秦叔逵客座教授等

摘录号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中都国中都期肝胰脏症状阿帕替尼防区病患：一项随机、阿司匹林依此、双盲III期研究课题

专场：肾脏胰脏—胃十二指肠、血栓和实是

原作者：解放军八一该医院秦叔逵客座教授、四川大学宝兴该医院李秋客座教授等

摘录号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中都期患适度卵巢胰脏二次细胞内减灭术的一项随机III期测试：SOC1 / SGOG-OV2。

回顾：妇科胰脏症

原作者：南京大学附属中都山该医院臧荣余客座教授等

摘录：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈胰脏根治适度内膜切除术后除此以外病患中都的序贯放化学疗法对比分开放疗或该系统放化学疗法（STARS研究课题）：一项随机、依此、对外开放标签的III期测试。

开就会：妇科胰脏症

原作者：清华大学防治中都心黄鹤客座教授、刘继红客座教授等

摘录号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：除此以外吉非替尼对比化学疗法用作可切除的EGFR适度状的N1-N2期NSCLC-随机III期诊疗测试的最后总体穴居量化。

回顾：肺胰脏—非小细胞内大面积-地带/小细胞内/其他腰部

原作者：中山市当权者该医院吴一龙客座教授等

摘录号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR适度状寡重新近分配非小细胞内肺胰脏症状三终点站半胱氨酸趋化因子抑制剂合组或不合组积极前终点站大面积放疗：III期对外开放标签诊疗随机测试（SINDAS）的中都期结果（NCT02893332）。

回顾：肺胰脏-非小细胞内重新近分配

原作者：南充当权者该医院曾铭客座教授等

摘录：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类死亡-1（PD-1）的人源化IgG4单克隆抗体合组阿昔替尼用作白血病黏膜皮肤白血病状的Ib期研究课题的总穴居期和微生物研究课题量化。

回顾：细菌适度/皮肤胰脏

原作者：北京大学该医院郭军、盛锡楠客座教授等

摘录：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全适度和结果：共通CAR-T细胞内首次体液测试病患患/难治适度T细胞内急适度抗原内白血病（r/r T-ALL）的安全适度和。开就会：高效率开发中都的病患高效率-免疫病患。原作者：王岂料等摘录：3013的广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中都期十二指肠上皮细胞细胞内胰脏症状中都的系统设计：一项随机的对外开放标签II期测试（ORIENT-2）。开就会：肾脏胰脏-胃十二指肠胰脏、血栓胰脏和实是道胰脏原作者：徐建明客座教授等摘录：4511的广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D基因表达CAR-T细胞内对胃母细胞内瘤的根除适度病患开就会：中都枢神经系统原作者：代红久、孙斌、杨东、徐晖、朱贝贝、魏佳、赵旭东摘录：2522的广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中都期错配修复缺陷症状中都的系统设计开就会：高效率开发中都的病患学-免疫病患原作者：沈琳客座教授等摘录：3021的广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病患患/难治适度ACUTE抗原内白血病/淋巴瘤的首例体液诊疗测试开就会: 高效率开发适度病患学-免疫病患原作者简介：张明志，新近兴镇等摘录：3026的广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 雷利替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度羟基（T）合组系统设计于中都期实体瘤症状的Ib期研究课题开就会：发展适度病患学--分子抗病毒药物和微生物学原作者：龚继芳，沈琳客座教授等摘录：3523的广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组糖类和nedaplatin病患患适度或白血病十二指肠上皮细胞细胞内胰脏（ESCC）症状的II期研究课题。开就会：肾脏胰脏-胃十二指肠、血栓和实是道胰脏的研究课题原作者：王志强，李玉红，王德申，王凤华，任超，谭琼 王志强、李玉红、王德深、王凤华、任超、谭琼摘录：4522的广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开就会：肾脏胰脏-胃十二指肠胰脏、血栓胰脏和实是管胰脏的防区病患原作者：宋艳等摘录：4524的广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体网状RNA分类器用作初始解剖时检测高等级胰脏的唾液外体网状RNA分类器：一项多中都心的回顾适度研究课题开就会：外科生殖系统胰脏症---胰脏、睾丸胰脏和胰脏原作者简介：Liaoyuan Li等摘录：5522的广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积中都期宫颈胰脏并发化学疗法后的除此以外化学疗法开就会: 妇科胰脏症原作者简介： 李珉珉等摘录：6031的广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病患甲状腺胃适度胰脏的相关适度：基于ALTER01031测试的量化。就会话：腰部原作者：天津市人民政府该医院高明客座教授摘录：6526的广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、体积和年龄对安洛替尼病患后症状结局的影响: ALTER01031的亚组量化开就会：腰部原作者：天津市人民政府该医院高明客座教授摘录：6527的广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA量化分析I-IIIA期非小细胞内肺胰脏（NSCLC）症状术后患: GASTO1035和GASTO1018的结果开就会：肺胰脏-非小细胞内大面积-地带适度/小细胞内/小细胞内/其他胸科胰脏症原作者：Si-Yu Wang等摘录：9023的广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞内肺胰脏（NSCLC）中都EGFR半胱氨酸趋化因子抑制剂的新近型病毒适度机制开就会:肺胰脏-非小细胞内白血病肺胰脏原作者简介：赵昕，金玲玲，满宇，欧元人，双带，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧元人、双带、薛武、杨绍、范敏摘录：9528的广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1测试中都中都期细菌适度总穴居的替代终点开就会：细菌适度/皮肤胰脏原作者：聂润聪，袁书强，李元芳，陈英波，周志伟 聂润聪、袁书强、李元芳、陈英波、周志伟摘录：10030的广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病患患或白血病继发适度恶适度骨症状的II期研究课题开就会： 白血病原作者：唐丽娜，牛晓辉，黄克诚，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶摘录：11525的广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 中长期赞赏安罗替尼在中都期白血病症状多终点站病患中都的安全适度和。开就会：白血病原作者：姚伟涛，的王室强，姚，王欣，杜新近辉，田志浩，牛晓颖 姚伟涛、的王室强、姚、王鑫、杜鑫辉、田志超、牛晓英摘录：11526的广告：414